Key result
Early butyrate-producing bacteria enrichment predicts ulcerative colitis remission on infliximab.
Why the study?
Response to anti-TNF therapy varies widely in IBD, and the role of the gut microbiome in predicting early therapeutic outcomes remains unclear.
Do early microbial changes predict remission at week 14 in IBD patients treated with infliximab?
Do early microbial changes predict remission at week 14 in IBD patients treated with infliximab?
Early enrichment of short-chain fatty acid-producing bacteria during infliximab therapy is associated with successful treatment response in IBD patients.
No takes yet. Share an insight, caveat, or question.
May support early prediction of infliximab response in UC; hypothesis-generating and requires prospective validation.
Agudelo et al. (2026) studied this question. In ulcerative colitis patients, early enrichment of butyrate-producing bacteria characterized remitters by week 2, while non-remitters showed dominance of proteobacteria.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: